Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niko Zantl

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Molecular Cancer|June 26, 2010
Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1Henry Zall, Arnim Weber, Robert Besch, et al.
The Journal of Sexual Medicine|March 1, 2013
Surgical management of penile fracture and long-term outcome on erectile function and voidingGeorgios Hatzichristodoulou, Annika Dorstewitz, Jürgen E Gschwend, et al.
AJR. American Journal of Roentgenology|May 23, 2006
Comparison of 16-MDCT and MRI for characterization of kidney lesionsAmbros J Beer, Martin Dobritz, Niko Zantl, et al.
Urologia Internationalis|June 10, 2009
Influence of body mass index on operability, morbidity and disease outcome following radical cystectomyTobias Maurer, Jean Maurer, Margitta Retz, et al.
Deutsches Arzteblatt International|November 29, 2016
Medication and Treatment Adherence Following Hospital DischargeClaudia Greißing, Peter Buchal, Hans-Joachim Kabitz, et al.
European Radiology|August 24, 2004
MR cystography for bladder tumor detectionAmbros Beer, Bettina Saar, Niko Zantl, et al.
The Journal of Sexual Medicine|January 28, 2010
Vaginal carcinoma in a female-to-male transsexualThilo Ludwig Schenck, Thomas Holzbach, Niko Zantl, et al.
Oncotarget|April 9, 2016
Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PETAmbros J Beer, Sarah M Schwarzenböck, Niko Zantl, et al.
The Canadian Journal of Urology|June 19, 2012
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastasesUlf W Tunn, Amulf Stenzl, Wolfgang Schultze-Seemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trialAlain Ravaud, Robert Hawkins, Jason P Gardner, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Molecular Cancer|June 26, 2010
Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1Henry Zall, Arnim Weber, Robert Besch, et al.
The Journal of Sexual Medicine|March 1, 2013
Surgical management of penile fracture and long-term outcome on erectile function and voidingGeorgios Hatzichristodoulou, Annika Dorstewitz, Jürgen E Gschwend, et al.
AJR. American Journal of Roentgenology|May 23, 2006
Comparison of 16-MDCT and MRI for characterization of kidney lesionsAmbros J Beer, Martin Dobritz, Niko Zantl, et al.
Urologia Internationalis|June 10, 2009
Influence of body mass index on operability, morbidity and disease outcome following radical cystectomyTobias Maurer, Jean Maurer, Margitta Retz, et al.
Deutsches Arzteblatt International|November 29, 2016
Medication and Treatment Adherence Following Hospital DischargeClaudia Greißing, Peter Buchal, Hans-Joachim Kabitz, et al.
European Radiology|August 24, 2004
MR cystography for bladder tumor detectionAmbros Beer, Bettina Saar, Niko Zantl, et al.
The Journal of Sexual Medicine|January 28, 2010
Vaginal carcinoma in a female-to-male transsexualThilo Ludwig Schenck, Thomas Holzbach, Niko Zantl, et al.
Oncotarget|April 9, 2016
Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PETAmbros J Beer, Sarah M Schwarzenböck, Niko Zantl, et al.
The Canadian Journal of Urology|June 19, 2012
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastasesUlf W Tunn, Amulf Stenzl, Wolfgang Schultze-Seemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trialAlain Ravaud, Robert Hawkins, Jason P Gardner, et al.
Pageof 2